Engitix_Logo_RGB.jpg
Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer
05 sept. 2023 07h00 HE | Engitix Therapeutics
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...
Engitix_Logo_RGB.jpg
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
09 mai 2023 04h00 HE | Engitix Therapeutics
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Algernon Logo 1.png
Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil
03 juin 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new...